The latest from CDMOs, CMOs, and suppliers featuring PanTera, MilliporeSigma, Evonik, Seran Biosciences, Cellular Origins and 3P innovation.  

Chemicals/Chemical API Manufacturing 
* Radioisotope Company PanTera Raises $102 M To Fund Mfg Expansion 
Biologics Manufacturing 
* MilliporeSigma Launches New Single-Use Reactor for Linkers ADC Mfg 
Formulation Development/Drug Product Manufacturing 
* Evonik Opens Spray-Drying Facility for Excipients
* Seran Biosciences Expands Clinical-Scale Drug-Product Mfg Facility 
* Cellular Origins, 3P Innovation In Cell- & Gene-Therapy Mfg Process Pact 

---

Chemicals/Chemical API Manufacturing 

Radioisotope Company PanTera Raises $102 M To Fund Mfg Expansion 
PanTera, a Mol, Belgium-based producer of radioisotopes, has raised EUR 94 million ($102 million) for the construction of a production facility in Belgium. PanTera raised the money through EQT Life Sciences, an investment firm. 

PanTera was founded in 2022 with the primary goal of enabling large-scale production of actinium-225 (225Ac), which is used in a new class of targeted cancer treatments known as targeted alpha therapy. Targeted alpha therapies enable delivery of radiation to cancer cells by radioisotopes that emit highly energetic alpha particles. The company says that the radiation effect of the alpha particle is more localized compared to other approaches and as such can destroy the cancer cells to which it is attached without harming surrounding healthy tissue.   

Source: EQT Life Sciences 

---

Biologics Manufacturing 

MilliporeSigma Launches New Single-Use Reactor for Linkers ADC Mfg  
MilliporeSigma, the life science business of Merck KGaA, has launched a single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs). The Mobius ADC Reactor Reactor is tailored to meet the requirements for linking the necessary components in an ADC.  

Source: MorailliporeSigma   

---

Formulation Development/Drug Product Manufacturing 

Evonik Opens Spray-Drying Facility for Excipients 
Evonik, a manufacturer of excipients, active pharmaceutical ingredients, fine chemicals, and specialty chemicals, has opened a new spray-drying facility at its site in Darmstadt, Germany, for producing aqueous dispersions of its oral excipient, Eudragit, polymethacrylates used in drug delivery. The new plant operates using green electricity and steam generated from local waste incineration, saving more than 1,000 carbon dioxide equivalents per year. 

Source: Evonik 

---

Seran BioScience Expands Clinical-Scale Drug-Product Mfg Facility 
Serán BioScience, a Bend, Oregon-based CDMO, has completed an expansion to increase the number of process manufacturing suites at its facility in Bend, Oregon, from 6 to 14, adding approximately 130% more cGMP clinical manufacturing capacity. 

The additional eight suites will provide increased capacity for late-stage clinical trial supply for small-molecule medicines. The new suites are housed within the existing footprint of Serán’s campus in Bend, which includes 10 buildings and a combined 90,000 square feet of space. 

Source: Seran BioScience 

---

Cellular Origins, 3P Innovation In Cell- & Gene-Therapy Mfg Process Pact 
Cellular Origins, a provider of manufacturing platforms for cell and gene therapies,, has entered an agreement with 3P innovation, an engineering company and supplier of automated fill-finish equipment, to integrate 3P innovation’s cryoFIL cryovial filling platform within Cellular Origins’ robotic system, Constellation, to enable automated filling of cryovials within a closed and sterile environment. 

The partnership will undertake the physical and digital integration of cryoFIL within Constellation, centering around the development of a system for robotic docking with cryoFIL. The integration will allow manufacturing processes that require interfacing with vials and other open format containers to be fully automated.  

Source: 3P innovation